Immunome Ownership | Who Owns Immunome?

Overview Forecast RevenueFinancials Chart

Immunome Ownership Summary

Immunome is owned by 96.87% institutional investors, 11.47% insiders. Blackrock is the largest institutional shareholder, holding 36.46% of IMNM shares. PRIMECAP Odyssey Aggressive Growth is the top mutual fund, with 3.54% of its assets in Immunome shares.

IMNM Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Immunome	96.87%	11.47%	-8.34%
Sector	Healthcare Stocks	279.18%	10.62%	-189.80%
Industry	Biotech Stocks	63.96%	10.74%	25.30%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock	3.76M	36.46%	$45.48M
State street	2.36M	22.93%	$28.61M
T. rowe price investment management	5.50M	9.14%	$58.41M
Redmile group	4.83M	8.02%	$51.27M
Blackrock funding, inc. /de	4.12M	6.85%	$43.81M
Fmr	3.92M	6.51%	$41.62M
Ecor1 capital	3.88M	6.44%	$41.20M
Janus henderson group	3.46M	5.74%	$36.73M
Vanguard group	3.00M	4.99%	$31.90M
Price t rowe associates inc /md/	2.28M	3.79%	$24.24M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Opaleye management	2.04M	3.79%	$21.66M
Redmile group	4.83M	3.57%	$51.27M
Ecor1 capital	3.88M	1.56%	$41.20M
Sofinnova investments	746.82K	0.58%	$7.93M
Prosight management, lp	65.00K	0.24%	$786.50K
Emfo	11.84K	0.13%	$143.20K
Three bridge wealth advisors	27.61K	0.10%	$293.27K
Woodline partners lp	980.92K	0.07%	$10.42M
Magnus financial group	53.54K	0.05%	$568.55K
Stoneridge investment partners	11.55K	0.04%	$123.00K

Top Buyers

Holder	Shares	% Assets	Change
Blackrock	3.76M	0.00%	2.93M
State street	2.36M	0.00%	2.16M
Opaleye management	2.04M	3.79%	802.50K
Jpmorgan chase	648.61K	0.00%	624.04K
Renaissance	316.00K	0.01%	304.70K

Top Sellers

Holder	Shares	% Assets	Change
Vestal point capital, lp	-	-	-1.00M
Avidity partners management lp	-	-	-873.89K
Brown advisory	-	-	-860.78K
Victory capital management	-	-	-730.78K
Tang capital management	-	-	-720.00K

New Positions

Holder	Shares	% Assets	Change	Value
Millennium management	158.43K	0.00%	158.43K	$1.68M
Prosight management, lp	65.00K	0.24%	65.00K	$786.50K
Alps advisors	50.47K	0.00%	50.47K	$535.99K
Two sigma advisers, lp	48.20K	0.00%	48.20K	$511.88K
Scharf investments	44.39K	0.01%	44.39K	$471.41K

Sold Out

Holder	Change
National bank of canada /fi/	-1.00
Signaturefd	-13.00
Lindbrook capital	-38.00
Russell investments group	-46.00
Parallel advisors	-93.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2025	147	18.55%	76,924,342	44.29%	96	1.24%	108	54.29%	17	-51.43%
Dec 31, 2024	123	1.65%	53,309,287	3.16%	88	1.20%	69	4.55%	35	25.00%
Sep 30, 2024	121	5.22%	51,674,695	8.14%	85	1.35%	66	-13.16%	28	27.27%
Jun 30, 2024	115	7.48%	47,785,575	30.06%	79	2.12%	76	-12.64%	22	83.33%
Mar 31, 2024	107	81.36%	36,741,102	70.98%	61	4.77%	87	107.14%	12	100.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
PRIMECAP Odyssey Aggressive Growth	3.08M	3.54%	2.84M
T. Rowe Price US Small-Cap Core Equity	2.85M	3.28%	894.44K
T. Rowe Price Small-Cap Stock	2.85M	3.28%	81.89K
Fidelity Growth Compy Commingled Pl O	1.79M	2.97%	-
T. Rowe Price Health Sciences	2.28M	2.62%	-34.41K
Vanguard Total Stock Mkt Idx Inv	2.24M	2.58%	-
Fidelity Growth Compy Commingled Pl S	1.83M	2.11%	-
iShares Russell 2000 ETF	1.83M	2.11%	897.00
Vanguard US Total Market Shares ETF	1.64M	1.88%	-
T. Rowe Price Instl Small-Cap Stock	1.53M	1.76%	44.09K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jun 03, 2025	BIENAIME JEAN JACQUES	-	Buy	$46.90K
Mar 25, 2025	BIENAIME JEAN JACQUES	-	Buy	$60.68K
Mar 26, 2025	SIEGALL CLAY B	President and CEO	Buy	$999.46K
Mar 24, 2025	BIENAIME JEAN JACQUES	-	Buy	$57.47K
Mar 24, 2025	Tsai Philip	Chief Technology Officer	Buy	$103.57K

Insider Transactions Trends

Date	Buy	Sell
2025 Q2	1	-
2025 Q1	5	-
2024 Q4	4	-
2024 Q3	1	2
2024 Q2	3	-

IMNM Ownership FAQ

Who Owns Immunome?

Immunome shareholders are primarily institutional investors at 96.87%, followed by 11.47% insiders and -8.34% retail investors. The average institutional ownership in Immunome's industry, Biotech Stocks , is 63.96%, which Immunome exceeds.

Who owns the most shares of Immunome?

Immunome’s largest shareholders are Blackrock (3.76M shares, 36.46%), State street (2.36M shares, 22.93%), and T. rowe price investment management (5.5M shares, 9.14%). Together, they hold 68.53% of Immunome’s total shares outstanding.

Does Blackrock own Immunome?

Yes, BlackRock owns 36.46% of Immunome, totaling 3.76M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 45.48M$. In the last quarter, BlackRock increased its holdings by 2.93M shares, a 353.41% change.

Who is Immunome’s biggest shareholder by percentage of total assets invested?

Opaleye management is Immunome’s biggest shareholder by percentage of total assets invested, with 3.79% of its assets in 2.04M Immunome shares, valued at 21.66M$.

Who is the top mutual fund holder of Immunome shares?

PRIMECAP Odyssey Aggressive Growth is the top mutual fund holder of Immunome shares, with 3.54% of its total shares outstanding invested in 3.08M Immunome shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools